The availability of DANYELZA is expanding every day
Get treatment near homeAs the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy,
DANYELZA is paving the way
LEARN MORE ABOUT DANYELZA®
DANYELZA is the ONLY FDA-approved immunotherapy for high-risk
neuroblastoma that:
- Is specifically for RELAPSED or REFRACTORY disease
- Is HUMANIZED, or more closely resembles antibodies found in the human body
- May have the option to be administered in an OUTPATIENT setting,
based on what your child’s doctor decides
DANYELZA is used in combination with another medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF).